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Aims Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and
bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, tica-
grelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with
similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor
vs. clopidogrel in patients with DM or poor glycaemic control.
Methods
and results
We analysed patients with pre-existing DM (n ¼ 4662), including 1036 patients on insulin, those without DM
(n ¼ 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n ¼ 15 150). In patients with
DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76–1.03), all-cause mortality (HR:
0.82, 95% CI: 0.66–1.01), and stent thrombosis (HR: 0.65, 95% CI: 0.36–1.17) with no increase in major bleeding
(HR: 0.95, 95% CI: 0.81–1.12) with ticagrelor was consistent with the overall cohort and without signiﬁcant diabetes
status-by-treatment interactions. There was no heterogeneity between patients with or without ongoing insulin treat-
ment. Ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis in patients with HbA1c
above the median (HR: 0.80, 95% CI: 0.70–0.91; HR: 0.78, 95% CI: 0.65–0.93; and HR: 0.62, 95% CI: 0.39–1.00,
respectively) with similar bleeding rates (HR: 0.98, 95% CI: 0.86–1.12).
Conclusion Ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status
and glycaemic control, without an increase in major bleeding events.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Acute coronary syndromes † Diabetes † Ticagrelor † Clopidogrel † Mortality † Myocardial infarction
* Corresponding author. Tel: +46 18 611 91 28, Fax: +46 18 51 55 70, Email: stefan.james@ucr.uu.se
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
European Heart Journal (2010) 31, 3006–3016
doi:10.1093/eurheartj/ehq325Introduction
Patients with diabetes mellitus (DM) and acute coronary syn-
dromes (ACS) are particularly at high risk for recurrent cardiovas-
cular (CV) events including death.
1–3 Although clopidogrel
combined with aspirin has been used successfully to prevent
thrombotic events in patients with ACS,
4–6 patients with DM,
when compared with those without, have consistently been
shown to have higher on-treatment platelet reactivity and worse
clinical outcomes.
7–11 The mechanisms leading to poor response
to clopidogrel in patients with DM are not fully elucidated but
are likely multifactorial including genetic, metabolic, cellular, and
clinical factors.
7,12,13 More recent work suggests that reduced gen-
eration of the active clopidogrel metabolite may contribute to
poor clopidogrel responsiveness in patients with DM.
14,15 Prasu-
grel, a third generation thienopyridine with more favourable phar-
macokinetic and pharmacodynamic proﬁle than clopidogrel, has
been shown to overcome these limitations and was associated
with a numerically lower rate of the primary composite ischaemic
endpoint in patients with DM in the Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON–
TIMI 38) study at the expense of an increase in major bleeds.
16
Ticagrelor is an oral non-thienopyridine P2Y12 inhibiting agent
with a reversible and direct action on the receptor that provides
faster, greater, and more consistent platelet inhibition than clopi-
dogrel.
17 The PLATelet inhibition and patient Outcomes
(PLATO) trial showed that ticagrelor was superior to clopidogrel
for the prevention of CV death, myocardial infarction (MI), or
stroke without a signiﬁcant increase in major bleeding in a broad
population of patients with ACS.
18 Establishing the clinical impact
of ticagrelor vs. clopidogrel in patients with DM was a pre-speciﬁed
aim of the PLATO trial and is reported here.
Methods
The PLATO trial randomized 18 624 patients with ST-segment
elevation or non-ST-segment elevation ACS, with onset during the
previous 24 h to ticagrelor or clopidogrel as soon as possible after
admission. Details of study design, patients, outcome deﬁnitions, and
results have been published.
18,19
Ticagrelor was given in a loading dose of 180 mg followed by 90 mg
twice daily. Patients randomized to clopidogrel were given a mainten-
ance dose of 75 mg daily. Those who were clopidogrel naı ¨ve received a
300-mg loading dose. An additional 300-mg dose was allowed pre PCI.
All patients received acetylsalicylic acid unless intolerant. The random-
ized treatment continued for a minimum of 6 to a maximum of 12
months with a median duration of study treatment of 9.1 months.
The primary efﬁcacy variable was time to ﬁrst occurrence of any
event from the composite of death from vascular causes, MI, or
stroke. The primary safety variable was the time to ﬁrst occurrence
of any PLATO-deﬁned major bleeding.
19 Diabetic status and
whether or not patients were on insulin treatment were assessed at
the time of randomization. Venous blood samples were obtained via
a direct venous puncture after randomization in a non-fasting state.
After centrifugation serum was frozen at 2208C in aliquots and sent
for central laboratory analysis of glucose and haemoglobin A1c
(HbA1c) concentration.
Statistical analyses
Patient characteristics were compared by DM status using x
2 and Wil-
coxon’s rank-sum tests. We pre-speciﬁed to report treatment effects
for primary and secondary efﬁcacy and safety events by DM status, the
median of serum glucose (6.8 mmol/L), and the median of percentage
HbA1c (6.0%). The Kaplan–Meier estimates were plotted by treat-
ment group, dichotomized HbA1c, and DM status. The Cox pro-
portional hazards models were used to investigate univariable
relationships between diabetes-related variables (DM, serum glucose,
and HbA1c as continuous variables, DM type, or insulin treatment)
and endpoint. The interactions between treatment group and diabetes-
related variables were evaluated with the addition of treatment and the
treatment-by-diabetes variable interaction. The multivariable Cox
regression models were ﬁtted for the primary efﬁcacy endpoint, the
primary safety endpoint, and all-cause mortality. Forward and back-
ward selections were used with the following covariates: age, sex,
prior MI, heart failure, hypertension, smoking, height, weight, previous
percutaneous coronary intervention, coronary artery bypass surgery,
ST elevation or left bundle branch block on ECG at entry, estimated
creatinine clearance, heart rate, peripheral artery disease, prior
tachyarrhythmia, blood pressure, and prior angina pectoris. The
models were repeated with the inclusion of DM, HbA1c, or glucose
and the randomized treatment-by-diabetes variable interaction was
allowed to enter if signiﬁcant. Subgroups based on intended treatment
strategy, ST elevation at entry, and creatinine clearance were tested
using the Cox models with the inclusion of the three-way interaction
of DM, treatment, and subgroup.
All analyses were performed according to the intention-to-treat
principle, utilizing SAS
w version 9.1. A two-sided P-value of 0.05 was
regarded statistically signiﬁcant for overall treatment differences.
Results
Patients
Among the 18 624 patients randomized in the PLATO study 4662
(25%) were reported as having DM by the investigators (Table 1).
Patients with DM more often had multiple CV risk factors. The
majority (96%) was reported as type 2. Prior to randomization,
almost one-fourth of the diabetic patients were on long-term
insulin treatment, and more than half were treated with insulin
and 84% were treated with any anti-diabetic medications during
the initial hospitalization (Table 2). Furthermore, patients with
DM were less often intended for an invasive treatment strategy
and underwent coronary angiography and PCI less often but had
coronary artery bypass surgery performed more often during
the course of the study. At discharge more patients with DM
were diagnosed with non-ST-elevation ACS and fewer with
ST-elevation MI compared with patients without DM.
Baseline characteristics, medications, and procedures were well
matched between the randomized treatment groups (Supplemen-
tary material online, Tables S6 and S7).
Outcomes in relation to diabetes status
Diabetes mellitus was strongly associated with all evaluated ischae-
mic and bleeding endpoints (Tables 3 and 4). Also after adjustment
for other signiﬁcant clinical and laboratory predictors of outcome
in multivariable analyses, DM was signiﬁcantly associated with
higher incidences of the primary composite outcome, mortality,
Ticagrelor in diabetes and acute coronary syndromes 3007Figure 1 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) total mortality
and (C) major bleeding in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with diabetes at baseline (blue lines) and no
diabetes (red lines).
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analysed as continuous variables were also signiﬁcantly associated
with the evaluated ischaemic and bleeding endpoints. Haemoglobin
A1c had a stronger association with the primary composite end-
point (x
2: 38, P ¼ 0.001 vs. 30, P ¼ 0.001) and all-cause mortality
(x
2: 31, P ¼ 0.001 vs. 22, P ¼ 0.001) but a weaker association
with major bleeding (x
2: 21, P ¼ 0.001 vs. 25, P ¼ 0.001) than dia-
betes status (data not shown).
Outcomes in relation to diabetes status
and randomized treatment
Ticagrelor signiﬁcantly reduced the primary composite endpoint
and also, separately, all-cause mortality, MI, and stent thrombosis
in patients without DM (Figure 1A and B). In the smaller subgroup
of patients with DM, this beneﬁt was consistent with the overall
trial results but did not reach nominal statistical signiﬁcance. No
diabetes status-by-treatment interaction was found (Table 4).
Figure 2 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction and stroke and (B) major bleeding
in the ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with levels of HbA1c at baseline above median of 6% (blue lines)
and below median of 6% (red lines).
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clopidogrel groups independent of DM status (Figure 1C). Inter-
action tests were not signiﬁcant irrespective of bleeding type and
deﬁnition (i.e. PLATO major, fatal or life threatening, or TIMI
major). PLATO-deﬁned major bleeding events unrelated to
CABG were numerically more frequent in the ticagrelor
group, whereas bleeding events related to CABG were numerically
more frequent in the clopidogrel group irrespective of
diabetic status and with no heterogeneity between the groups
(Table 4).
Outcomes in relation to level of
metabolic control and randomized
treatment
Higher serum levels of HbA1c and higher glucose levels were both
strongly associated with a higher incidence of all evaluated
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Table 1 Patient characteristics at baseline
Characteristic Diabetes (n 5 4662) No diabetes (n 5 13 951) P-value
Age [median (25th–75th percentile)] 64 (56–72) 61 (53–70) ,0.0001
Age ≥75 years [% (n)] 17.4 (809) 14.8 (2067) ,0.0001
Gender, women [% (n)] 34.8 (1624) 26.2 (3660) ,0.0001
Body weight [median (25th–75th percentile)] 81 (70–93) 79 (70–89) ,0.0001
Body weight , 60 kg [% (n)] 5.9 (274) 7.4 (1038) 0.0011
BMI [median (25th–75th percentile)] 28.7 (25.7–32.0) 27.0 (24.5–29.8) ,0.0001
Waist circumference [median (25th–75th percentile)] 102 (93–110) 97 (89–105) ,0.0001
Race [% (n)] ,0.0001
Black 2.1 (98) 0.9 (131)
Caucasian 89.4 (4169) 92.5 (12 898)
Oriental 6.8 (319) 5.6 (777)
Other 1.6 (76) 1.0 (145)
CV risk factors [% (n)]
Habitual smoker 24.8 (1156) 39.6 (5522) ,0.0001
Hypertension 81.6 (3802) 60.1 (8381) ,0.0001
Dyslipidaemia 59.7 (2782) 42.3 (5907) ,0.0001
History [% (n)]
Angina pectoris 54.0 (2517) 41.9 (5841) ,0.0001
Myocardial infarction 27.0 (1261) 18.4 (2563) ,0.0001
Congestive heart failure 9.4 (440) 4.4 (610) ,0.0001
Percutaneous coronary intervention 18.2 (847) 11.8 (1645) ,0.0001
Coronary artery bypass graft 10.0 (464) 4.6 (642) ,0.0001
Transient ischaemic attack 3.4 (157) 2.5 (342) 0.0011
Non-haemorrhagic stroke 5.8 (269) 3.2 (453) ,0.0001
Peripheral arterial disease 9.2 (431) 5.1 (713) ,0.0001
Chronic renal disease 7.8 (362) 3.0 (423) ,0.0001
Treatment [% (n)]
OL clopidogrel dose ≥ 600 mg before randomization 9.0 (421) 13.2 (1846) ,0.0001
Total clopidogrel (OL + IP) dose ≥ 600 mg before
randomization to 24 h after ﬁrst dose
16.4 (765) 22.1 (3080) ,0.0001
Randomized to ticagrelor 49.9 (2326) 50.2 (6999) 0.7445
Planned invasive 66.7 (3109) 73.8 (10 289) ,0.0001
Baseline labs [median (25th–75th percentile)]
Glucose (mmol/L) 9.8 (7.2–13.2) 6.4 (5.6–7.7) ,0.0001
Haemoglobin A1c (%) 7.6 (6.7–9.0) 5.8 (5.6–6.1) ,0.0001
Creatinine clearance (mL/min) 76.4 (58.0–96.6) 81.6 (64.7–99.6) ,0.0001
First central troponin I
a (mmol/L) 2.1 (0.2–11.7) 2.1 (0.2–12.0) 0.2857
OL, open label; IP, investigational product.
aAdvia Centaur TnI-Ultra Immunoassay (Siemens).
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HbA1c levels above the median of 6%, the primary composite
outcome was signiﬁcantly reduced with ticagrelor vs. clopidogrel
by 2.8% (20% relative), all-cause mortality by 1.8% (22% relative)
but with similar major bleeding rates (Table 4, Figure 2). For
patients with glucose levels above the median of 6.8 mmol/L, the
primary composite endpoint was signiﬁcantly reduced with ticagre-
lor vs. clopidogrel by 2.3% (15% relative), all-cause mortality by
1.8% (21% relative) but with a similar absolute major bleeding
rate. There were no signiﬁcant interactions for
treatment-by-glucose or -HbA1c level. Also in patients without a
diagnosis of diabetes at baseline above the median levels of
glucose or HbA1c were associated with higher event rates, and
the reduction in the primary endpoint and MI by ticagrelor was
more pronounced in patients with levels of HbA1c above the
median with signiﬁcant treatment-by-HbA1c interactions (Sup-
plementary material online, Table S8).
The outcome measures were also consistent across various sub-
groups of patients with DM with no interactions for the type of
ACS (ST-elevation MI or non-ST-elevation ACS), initial intended
treatment strategy (non-invasive or invasive treatment), and
degree of renal function (data not shown).
Outcomes in relation to type of diabetes
and randomized treatment
Insulin-treated patients had higher rates of all evaluated endpoints
when compared with diabetic patients not on insulin (Table 5). The
treatment effects of ticagrelor vs. clopidogrel were consistent with
the overall trial results with no treatment-by-diabetes type
(insulin-/non-insulin-treated or type 1/type 2) interaction. Thus,
DM patients on insulin had a numerical 5.1% absolute (22% rela-
tive) reduction in the primary composite outcome. No signiﬁcant
difference was found in all-cause mortality or major bleeding
(Table 5).
Discussion
The present study conﬁrms the increased risk of adverse ischaemic
events, mortality, and bleeding associated with DM in patients
treated for ACS as shown in several other clinical trials and data-
bases.
1 In the present study, patients with DM had more often
several high-risk criteria including reduced renal function, and
less often underwent angiography and PCI when compared with
non-diabetic patients. Despite good adherence to guidelines
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Table 2 Medication and procedures during study and ﬁnal diagnosis according to diabetes status
Characteristic Diabetes (n 5 4662) No diabetes (n 5 13 951) P-value
Medications from index event to end of hospitalization [% (n)]
Aspirin 97.1 (4525) 97.2 (13 549) 0.5984
Beta-blockers 83.7 (3899) 86.4 (12 042) ,0.0001
ACE inhibitors and/or angiotensin receptor blockers 89.8 (4186) 81.0 (11 287) ,0.0001
Cholesterol lowering (statin) 93.5 (4359) 94.0 (13 099) 0.2394
Ca-channel blockers 29.7 (1385) 18.9 (2638) ,0.0001
Diuretics 49.4 (2301) 33.7 (4692) ,0.0001
Glycoprotein IIb/IIIa inhibitors 24.0 (1119) 28.1 (3918) ,0.0001
Insulin 55.2 (2573) 5.5 (766) ,0.0001
Any anti-diabetic medication 84.2 (3924) 6.4 (886) ,0.0001
Procedures [% (n)]
Coronary angiography before discharge 77.4 (3607) 82.9 (11 562) ,0.0001
Coronary angiography during study 82.9 (3863) 86.8 (12 116) ,0.0001
PCI before discharge 53.9 (2514) 63.4 (8849) ,0.0001
PCI during study 58.0 (2703) 66.5 (9274) ,0.0001
Stenting 54.1 (2520) 62.9 (8769) ,0.0001
With bare-metal stent only 33.0 (1538) 45.0 (6275) ,0.0001
With ≥1 drug-eluting stent 21.1 (982) 17.9 (2494) ,0.0001
CABG before discharge 6.4 (300) 4.8 (670) ,0.0001
CABG during study 13.2 (617) 9.2 (1282) ,0.0001
Final diagnosis
a [% (n)] ,0.0001
STEMI 28.7 (1336) 40.8 (5690)
NSTEMI 47.6 (2217) 41.1 (5738)
Unstable angina pectoris 20.9 (975) 15.3 (2137)
Other 2.8 (130) 2.6 (359)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery.
aThe type of ACS deﬁned using the ﬁnal diagnosis of index event.
Ticagrelor in diabetes and acute coronary syndromes 3011concerning pharmacological therapies and invasive procedures in
patients with DM, the mortality was 80% higher than in patients
without DM. The risk of MI, stent thrombosis, and major bleeding
were also considerably higher. Furthermore, patients with insulin-
treated diabetes had a 50% higher mortality rate compared with
DM patients not on insulin.
We demonstrated that a more potent and consistent inhibition
of platelet aggregation with ticagrelor reduced ischaemic events
and mortality with no signiﬁcant increase in overall major bleeding
complications. Non-CABG-related major bleeding events were,
however, more frequent than in the clopidogrel group. These ﬁnd-
ings were consistent among both diabetic and non-diabetic
patients.
Prasugrel compared with clopidogrel administered after angiogra-
phyreducedtheprimaryendpointofCVdeath,MI,orstrokeby4.8%
(30% relative) in diabetic patients in a subgroup analysis of the
TRITON–TIMI 38 trial.
17 Ticagrelor compared with clopidogrel
administered prior to, or at the time of, randomization with higher
doses in the PLATO trial reduced the primary endpoint in diabetic
patients by 2.1% (23% relative) that did not reach nominal statistical
signiﬁcance. Similar to the subgroup analysis of prasugrel vs. clopido-
grelintheTRITON–TIMI38trial,therewasnostatisticallysigniﬁcant
interaction for the primary outcome by DM status or by diabetes
type. However, patients with above the median levels of HbA1c at
randomizationexperiencedasigniﬁcant2.8%absolute(30%relative)
reduction in the primary composite endpoint with ticagrelor vs. clo-
pidogrel. All-cause death was numerically reduced with ticagrelor in
patients with diabetes and signiﬁcantly in patients with above the
median levels of HbA1c or glucose with no signiﬁcant
diabetes-by-randomizedgroupinteractions.Furthermore,inpatients
with above the median levels of HbA1c or glucose ticagrelor signiﬁ-
cantly reduced the rate of MI with 1.8% (22 and 21% relative). In the
...............................................................................................................................................................................
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Table 3 Association of diabetes-related variables with endpoints
Characteristic
a x
2 HR (95% CI) P-value
Efﬁcacy endpoints
CV death, MI, or stroke
Diabetes 108.78 1.66 (1.51–1.82) ,0.0001
Baseline glucose (truncated)
b 67.22 1.12 (1.09–1.15) ,0.0001
Baseline HbA1c (truncated)
b 90.72 1.30 (1.23–1.37) ,0.0001
All-cause death
Diabetes 78.87 1.84 (1.61–2.10) ,0.0001
Baseline glucose (truncated)
b 83.47 1.21 (1.16–1.25) ,0.0001
Baseline HbA1c (truncated)
b 75.14 1.40 (1.30–1.51) ,0.0001
MI
Diabetes 44.09 1.53 (1.35–1.73) ,0.0001
Baseline glucose (truncated)
b 9.92 1.06 (1.02–1.10) 0.0016
Baseline HbA1c (truncated)
b 34.85 1.24 (1.15–1.33) ,0.0001
Deﬁnite stent thrombosis
c
Diabetes 1.91 1.26 (0.91–1.77) 0.1673
Baseline glucose (truncated)
b 12.68 1.19 (1.08–1.31) 0.0004
Baseline HbA1c (truncated)
b 5.20 1.24 (1.03–1.50) 0.0226
Safety endpoints
Major bleeding
Diabetes 48.13 1.41 (1.28–1.55) ,0.0001
Baseline glucose 14.91 1.03 (1.01–1.04) 0.0001
Baseline HbA1c 20.39 1.07 (1.04–1.11) ,0.0001
Non-CABG major bleeding
Diabetes 14.50 1.38 (1.17–1.62) 0.0001
Baseline glucose 9.78 1.04 (1.01–1.06) 0.0018
Baseline HbA1c 0.03 1.00 (0.95–1.06) 0.8676
CABG-related major bleeding
Diabetes 34.16 1.42 (1.26–1.60) ,0.0001
Baseline glucose 5.49 1.02 (1.00–1.04) 0.0191
Baseline HbA1c 28.65 1.10 (1.06–1.14) ,0.0001
aGlucose and HbA1c values are treated as linear for the range of values for the safety endpoints.
bFor efﬁcacy outcomes, glucose values ,5 and .10 are treated as 5 and 10, respectively. For efﬁcacy outcomes, HbA1c values .8 are treated as 8.
cOf the 11 289 patients who received a stent, 2520 had DM.
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Table 4 Outcome in relation to diabetes status and glucose metabolic control
n Overall Ticagrelor Clopidogrel HR (95% CI) P-value (interaction)
CV death, myocardial infarction, or stroke
No diabetes 13 951 9.3 (1219) 8.4 (555) 10.2 (664) 0.83 (0.74–0.93) 0.49
Diabetes 4662 15.2 (659) 14.1 (309) 16.2 (350) 0.88 (0.76–1.03)
Glucose , 6.8 mmol/L 7604 8.9 (630) 8.0 (284) 9.7 (346) 0.83 (0.71–0.98) 0.52
Glucose ≥ 6.8 mmol/L 7646 12.8 (925) 11.7 (428) 14.0 (497) 0.85 (0.74–0.96)
HbA1c , 6.0% 7260 8.6 (593) 8.2 (288) 9.0 (305) 0.93 (0.79–1.09) 0.24
HbA1c ≥ 6.0% 7890 12.8 (947) 11.4 (419) 14.2 (528) 0.80 (0.70–0.91)
All-cause death
No diabetes 13 951 4.3 (564) 3.7 (246) 5.0 (318) 0.77 (0.65–0.91) 0.66
Diabetes 4662 7.9 (341) 7.0 (153) 8.7 (188) 0.82 (0.66–1.01)
Glucose , 6.8 mmol/L 7604 3.6 (252) 3.1 (110) 4.1 (142) 0.79 (0.62–1.01) 0.38
Glucose ≥ 6.8 mmol/L 7646 6.9 (492) 6.0 (218) 7.8 (274) 0.79 (0.66–0.94)
HbA1c , 6.0% 7260 3.8 (256) 3.4 (114) 4.2 (142) 0.79 (0.62–1.01) 0.71
HbA1c ≥ 6.0% 7890 6.5 (475) 5.6 (206) 7.4 (269) 0.78 (0.65–0.93)
Myocardial infarction
No diabetes 13 951 5.6 (731) 5.0 (329) 6.2 (402) 0.81 (0.70–0.94) 0.32
Diabetes 4662 8.7 (366) 8.4 (175) 9.1 (191) 0.92 (0.75–1.13)
Glucose , 6.8 mmol/L 7604 5.9 (415) 5.5 (192) 6.2 (223) 0.87 (0.72–1.06) 0.84
Glucose ≥ 6.8 mmol/L 7646 7.2 (500) 6.4 (227) 7.9 (273) 0.82 (0.68–0.97)
HbA1c , 6.0% 7260 5.4 (369) 5.1 (179) 5.8 (190) 0.92 (0.75–1.13) 0.47
HbA1c ≥ 6.0% 7890 7.5 (540) 6.8 (241) 8.2 (299) 0.81 (0.68–0.96)
Deﬁnite stent thrombosis
No diabetes 8766 1.5 (130) 1.3 (53) 1.8 (77) 0.68 (0.48–0.97) 0.89
Diabetes 2518 2.0 (47) 1.6 (18) 2.4 (29) 0.65 (0.36–1.17)
Glucose , 6.8 mmol/L 4383 1.1 (48) 1.2 (25) 1.0 (23) 1.07 (0.61–1.89) 0.45
Glucose ≥ 6.8 mmol/L 4882 1.9 (89) 1.5 (33) 2.4 (56) 0.60 (0.39–0.93)
HbA1c , 6.0% 4592 1.4 (62) 1.4 (30) 1.4 (32) 0.91 (0.55–1.50) 0.51
HbA1c ≥ 6.0% 4636 1.7 (74) 1.3 (28) 2.0 (46) 0.62 (0.39–1.00)
Major bleeding, PLATO deﬁned
No diabetes 13 798 10.4 (1298) 10.8 (674) 10.0 (624) 1.08 (0.97–1.20) 0.21
Diabetes 4621 14.4 (592) 14.1 (287) 14.8 (305) 0.95 (0.81–1.12)
Glucose , 6.8 mmol/L 7604 10.7 (734) 11.0 (370) 10.4 (364) 1.04 (0.90–1.20) 0.35
Glucose ≥ 6.8 mmol/L 7646 11.5 (790) 12.0 (412) 11.1 (378) 1.09 (0.94–1.25)
HbA1c , 6.0% 7260 9.8 (647) 10.9 (357) 8.8 (290) 1.22 (1.05–1.43) 0.08
HbA1c ≥ 6.0% 7890 12.4 (874) 12.3 (428) 12.6 (446) 0.98 (0.86–1.12)
Non-CABG-related major bleeding, PLATO deﬁned
No diabetes 13 798 3.8 (461) 4.1 (253) 3.4 (208) 1.22 (1.01–1.46) 0.69
Diabetes 4621 5.2 (207) 5.5 (109) 4.9 (98) 1.13 (0.86–1.49)
Glucose , 6.8 mmol/L 7604 3.7 (243) 3.9 (126) 3.4 (117) 1.10 (0.86–1.42) 0.97
Glucose ≥ 6.8 mmol/L 7646 4.4 (297) 4.9 (168) 3.9 (129) 1.30 (1.03–1.64)
HbA1c , 6.0% 7260 3.5 (228) 4.2 (132) 2.9 (96) 1.36 (1.05–1.77) 0.47
HbA1c ≥ 6.0% 7890 4.5 (307) 4.8 (163) 4.2 (144) 1.16 (0.93–1.46)
CABG-related major bleeding, PLATO deﬁned
No diabetes 13 798 7.0 (871) 6.8 (430) 7.1 (441) 0.97 (0.85–1.11) 0.51
Diabetes 4621 9.9 (402) 9.3 (189) 10.4 (213) 0.90 (0.74–1.09)
Glucose , 6.8 mmol/L 7604 7.4 (510) 7.4 (252) 7.4 (258) 1.00 (0.84–1.19) 0.32
Glucose ≥ 6.8 mmol/L 7646 7.6 (515) 7.5 (254) 7.7 (261) 0.97 (0.81–1.15)
HbA1c , 6.0% 7260 6.6 (436) 6.9 (230) 6.3 (206) 1.10 (0.91–1.33) 0.31
Continued
Ticagrelor in diabetes and acute coronary syndromes 3013TRITON–TIMI38trial,therewasanumericalreductioninCVdeath
andasigniﬁcantreductioninMIwith5%(40%relative)withprasugrel
vs. clopidogrel in diabetic patients. The relatively lower reduction in
MIwith ticagrelor inthePLATO trialcompared with prasugrel inthe
TRITON–TIMI 38 trial may be explained by the higher average
loadingdoseofclopidogrelintheclopidogrelarmandpre-treatment
with clopidogrel in half of the patients in the ticagrelor arm.
19 Fur-
thermore, the TRITON–TIMI 38 trial results depend on early peri-
procedural MI determined by enzyme changes alone, detection of
which was facilitated by delay of subject enrolment until after coron-
aryangiography.PLATOenrolledpatientssoonaftertheindexevent,
making early MI detection more difﬁcult. Thus, any apparent differ-
ence in MI results between trials likely results from study design
rather than actual outcome. Therefore, any comparison between
PLATO and TRITON regarding early ischaemic events should be
performed with caution.
No signiﬁcant interactions for diabetes status with the respect-
ive primary composite outcomes were found in the CURE trial
(clopidogrel vs. placebo in unstable angina) or in the CURRENT
OASIS 7 trial
20 (evaluating high- vs. low-dose clopidogrel in
patients undergoing PCI). Furthermore, neither of these trials
could demonstrate statistically signiﬁcant differences between the
randomized treatment arms concerning the primary composite
endpoint or any of the secondary outcome events.
Given high platelet reactivity levels in diabetic patients,
9 it
remains an open question whether a higher dose of ticagrelor
could have resulted in greater clinical beneﬁt in terms of reduction
in ischaemic events in the current trial. However, predicted
steady-state plasma exposure of ticagrelor and its active metabolite
were not different in patients with or without DM (AZ internal
data). Nevertheless, very high levels of platelet inhibition may
not be sufﬁcient for adequate protection against ischaemic
...............................................................................................................................................................................
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Table 4 Continued
n Overall Ticagrelor Clopidogrel HR (95% CI) P-value (interaction)
HbA1c ≥ 6.0% 7890 8.4 (591) 8.0 (278) 8.8 (313) 0.91 (0.77–1.07)
Major bleeding, TIMI deﬁned
No diabetes 13 798 7.3 (910) 7.6 (476) 7.0 (434) 1.10 (0.96–1.25) 0.10
Diabetes 4621 9.5 (385) 9.0 (181) 9.9 (204) 0.90 (0.74–1.10)
Glucose , 6.8 mmol/L 7604 7.4 (508) 7.7 (261) 7.2 (247) 1.09 (0.91–1.29) 0.07
Glucose ≥ 6.8 mmol/L 7646 7.9 (537) 7.9 (269) 7.9 (268) 1.00 (0.84–1.18)
HbA1c , 6.0% 7260 6.9 (454) 7.5 (247) 6.3 (207) 1.18 (0.98–1.42) 0.05
HbA1c ≥ 6.0% 7890 8.4 (593) 8.2 (287) 8.7 (306) 0.96 (0.82–1.13)
CV, cardiovascular; CABG, coronary artery bypass grafting; TIMI, thrombolysis in myocardial infarction.
...............................................................................................................................................................................
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Table 5 Outcome in randomized groups in relation to type of diabetes
n Overall Ticagrelor Clopidogrel HR (95% CI) P-value (interaction)
CV death, MI, or stroke
Diabetes, no insulin
a 3625 13.7 (468) 13.1 (225) 14.2 (243) 0.93 (0.78–1.12) 0.30
Diabetes, insulin
a 1036 20.3 (190) 17.7 (84) 22.8 (106) 0.78 (0.58–1.03)
Diabetes, type 1 209 14.4 (28) 12.4 (13) 16.4 (15) 0.78 (0.37–1.63) 0.73
Diabetes, type 2 4451 15.2 (631) 14.2 (296) 16.1 (335) 0.89 (0.76–1.04)
All-cause death
Diabetes, no insulin
a 3625 7.0 (238) 6.2 (105) 7.8 (133) 0.79 (0.61–1.03) 0.66
Diabetes, insulin
a 1036 10.9 (102) 10.0 (48) 11.7 (54) 0.88 (0.60–1.30)
Diabetes, type 1 209 3.9 (8) 4.6 (5) 3.1 (3) 1.53 (0.37–6.41) 0.39
Diabetes, type 2 4451 8.1 (333) 7.2 (148) 9.0 (185) 0.81 (0.65–1.00)
Major bleeding
Diabetes, no insulin
a 3593 14.2 (458) 13.8 (217) 14.7 (241) 0.91 (0.76–1.09) 0.28
Diabetes, insulin
a 1027 15.2 (134) 15.1 (70) 15.1 (64) 1.12 (0.80–1.58)
Diabetes, type 1 208 14.8 (29) 18.0 (19) 11.1 (10) 1.79 (0.83–3.86) 0.08
Diabetes, type 2 4412 14.4 (563) 13.9 (268) 14.9 (295) 0.92 (0.78–1.09)
CV, cardiovascular; MI, myocardial infarction.
aOn insulin vs. no insulin treatment before index event.
S. James et al. 3014events in patients with DM. The prothrombotic condition that DM
constitutes
21 may require anti-thrombin or other long-term
anti-coagulation therapy for a more general prevention of CV
events among these high-risk patients.
The overall major bleeding rate was 4% higher (40% relative) in
patients with vs. without DM. Still in patients with DM, there was
no signiﬁcant difference in major bleeding rates between ticagrelor
and clopidogrel neither in patients with DM nor in patients with a
poor glycaemic control. No signiﬁcant differences in bleeding rates
(irrespective of type or severity) were observed between the ran-
domized treatment groups among patients with DM or with poor
glycaemic control on admission.
Limitations
Although pre-speciﬁed, the present study is a subgroup analysis of
the PLATO trial with its inherent limitations. The DM cohort of
4600 patients was not powered for showing a difference in the
primary outcome between the randomized groups. However,
the results were consistent with the overall trial results, and the
analyses based on diabetes status and levels of glucose and
HbA1c were pre-speciﬁed in the statistical analysis plan before
any statistical analyses were performed. Furthermore, randomiz-
ation was not stratiﬁed by diabetes status, type of diabetes, or
level of glycaemic control. Still, baseline characteristics were well
balanced between the randomized groups in patients with DM.
Conclusions
This pre-speciﬁed substudy from the PLATO trial showed that DM
and higher levels of glucose and HbA1c were strongly associated
with all evaluated ischaemic and bleeding endpoints and with
higher risks of the primary outcome and mortality in patients on
insulin treatment. Ticagrelor compared with clopidogrel reduced
the primary composite outcome of CV death, MI, or stroke. Fur-
thermore, total mortality and stent thrombosis were also
reduced without any signiﬁcant increase in overall major bleeding.
These effects were seen irrespective of diabetic status, insulin
treatment, and glycaemic control.
Supplementary material
Supplementary material is available at European Heart Journal online.
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